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Muscle wasting and cachexia have long been postu-
lated to be key determinants of cancer-related death,
but there has been no direct experimental evidence
to substantiate this hypothesis. Here, we show that
in several cancer cachexia models, pharmacological
blockade of ActRIIB pathway not only prevents
further muscle wasting but also completely reverses
prior loss of skeletal muscle and cancer-induced
cardiac atrophy. This treatment dramatically pro-
longs survival, even of animals in which tumor growth
is not inhibited and fat loss and production of proin-
flammatory cytokines are not reduced. ActRIIB
pathway blockade abolished the activation of the
ubiquitin-proteasome system and the induction of
atrophy-specific ubiquitin ligases in muscles and
also markedly stimulated muscle stem cell growth.
These findings establish a crucial link between
activation of the ActRIIB pathway and the develop-
ment of cancer cachexia. Thus ActRIIB antagonism
is a promising new approach for treating cancer
cachexia, whose inhibition per se prolongs survival.
INTRODUCTION
Cancer cachexia affects up to 80% of patients with advanced
cancers and accounts for nearly 30% of cancer-related deaths
(Acharyya et al., 2005; Fearon, 2008; Tisdale, 2009). However,
few therapeutic options are currently available for cancer
cachexia. A key feature of cachexia is the progressive depletion
of skeletal muscle mass, which occurs in concert with the loss of
body fat. Muscle wasting dramatically reduces the quality of life
but also appears to correlate with fatal outcomes. The mecha-
nism by which cancers provoke the loss of the host’s muscle
mass is presently thought to bemultifactorial. Various hormones,
cytokines and tumor-derived factors have been shown to influ-
ence muscle protein balance in normal and disease states,
through several major intracellular signal transduction systems.
While activation of the AKT pathway is associated with musclegrowth, in atrophying muscles there is an activation of FOXO
as well as NF-kB and possibly also Smad transcription factors,
which promote protein degradation (Glass, 2005; Sandri et al.,
2004). FOXO3 by itself induces a set of atrophy-related genes,
especially the muscle-specific ubiquitin ligases Atrogin-1 and
MuRF1, which promotes breakdown of myofibrillar apparatus,
and genes for autophagy (Cohen et al., 2009; Zhao et al.,
2007). However, it remains unclear which of these signaling
systems plays a dominant role in the pathogenesis of cancer-
associated muscle loss.
ActRIIB is a high affinity activin type 2 receptor and mediates
the signaling by a subset of TGF-b family ligands including
myostatin, activin, GDF11 and others (Lee & McPherron,
2001; Souza et al., 2008). Expression of a dominant negative
ActRIIB in transgenic mice results in skeletal muscle hyper-
trophy, suggesting an important role of ActRIIB pathway in
limiting muscle growth (Lee & McPherron, 2001). Myostatin
null mutations also lead to skeletal muscle hypertrophy in
multiple species including humans, whereas forced myostatin
overexpression in adult mice leads to systemic muscle wasting
(Schuelke et al., 2004; Zimmers et al., 2002). In addition, in
inhibin-deficient mice, activins are deregulated, leading to
gonadal tumors and marked cachexia (Matzuk et al., 1994).
Therefore, ActRIIB ligands appear critical in regulating muscle
mass (Lee et al., 2005).
Increased signaling by the ActRIIB pathway has been impli-
cated in many cancers (Costelli et al., 2008; Harada et al.,
1996; Otani et al., 2001; Petraglia et al., 1998; Seder et al.,
2009; Thomas, et al., 1997; Wildi et al., 2001), but its possible
importance in pathogenesis of cancer cachexia remain obscure.
In these investigations we set out (1) to examine in animal
models of cancer cachexia the possible therapeutic impact of
blocking ActRIIB pathway on muscle wasting and survival, and
(2) to define the mechanisms by which ActRIIB pathway may
modify the course of cancer cachexia. To antagonize the
ActRIIB pathway activity, we have administered an ActRIIB
decoy receptor referred to as sActRIIB in multiple cancer
cachexia models, including the colon 26 (C26) tumor-bearing
mice and inhibin-deficient mice, as well as nude mice bearing
human G361 melanoma and TOV-21G ovarian carcinoma xeno-
grafts. Bearing tumors of distinctly different origins, these
models mimic human cancer cachexia with a promouncedCell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc. 531
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Figure 1. Changes in Body Weights and Survival Rates in C26
Tumor-Bearing Mice Resulting from sActRIIB Administered at
Different Stages of Cachexia
Arrows point to the timings of the 1st dose at day 5 (A) and day 14 (B) post
tumor implantation, respectively, in two separate experiments. C26 mice
were treated with sActRIIB (10 mg/kg, SC, weekly) or PBS (n = 20). Age-
matched normal control mice were treated with PBS (n = 10). ***p < 0.001;
###p < 0.0001.
See also Figures S1 and S2.loss of muscle mass at low tumor burden and display a dramatic
wasting that is eventually lethal (Matzuk et al., 1994; Mori et al.,
1991; Tanaka et al., 1990). The present studies demonstrate that
sActRIIB not only prevents further wasting, but also fully
reverses skeletal muscle loss and atrophy of the heart, thereby
dramatically prolonging survival of the tumor-bearing animals.
Importantly, in the C26 model, these marked effects are seen
even without any effect on tumor growth, adiposity, or levels
of inflammatory cytokines. Our data reveal that ActRIIB antago-
nism reverses wasting by blocking the activation of muscle
protein breakdown and stimulating muscle stem cell growth.
Thus, ActRIIB pathway inhibition appears to have therapeutic
potential for treating various types of muscle wasting, especially
cancer cachexia.
RESULTS
sActRIIB Is a Potent Inhibitor of Myostatin
and Activin A Signaling
We measured the ligand-neutralizing activities of recombinant
sActRIIB using C2C12 myoblasts stably transfected with a
luciferase reporter for Smad2/3 signaling, as detailed in Experi-
mental Procedures. sActRIIB potently inhibited both myostatin-
and activin-mediated Smad2/3 signal transduction with IC50
values around 1.1 nM against myostatin and 3.6 nM against
activin A (Figure S1A available online). The half-life (T1/2) of
sActRIIB in mice was longer than 10 days. Administration of of
a single dose of sActRIIB to adult C57Bl/6 mice led to dose-
dependent increases in body weight and lean body mass
(Figure S1B).
ActRIIB Antagonism Reverses Muscle Loss
and Prolongs Survival in C26 Tumor-Bearing Mice
The C26 tumor implanted mice manifested a lethal wasting
syndrome characterized by progressive weight loss and death
(Tanaka et al., 1990). As shown in Figure 1A, weight loss in these
tumor-bearing mice began around day 5 after implantation, and
within 2–3 weeks of implantation, their body weights declined
by > 20%. Analysis of individual body weight changes indicates
that when the tumor-free body weight decreased by > 25% after
the tumor implantation (i.e., by > 35% compared to the normal
control mice), deaths occurred (Figure S2). We administered
sActRIIB to this model at different stages of cachexia and
analyzed the changes in body weights and survival rates.
When administration was begun when weight loss first became
evident, weekly injection of sActRIIB not only completely pre-
vented further weight loss, but even caused a rapid gain in
body weight which soon exceeded that in non-implanted control
mice (Figure 1A). Furthermore, when treatment was initiated
during advanced cachexia, when more than 10% body weight
was lost, the sActRIIB treatment rapidly and fully reversed the
weight loss back to weights of normal control mice (Figure 1B).
Remarkably, the gains in body weight were associated with
a profound prolongation of survival in the tumor-bearing animals
(p < 0.0001) (Figures 1A and 1B). Thus, regardless of the timing
of the first dose during the course of cachexia, sActRIIB was
able to reverse weight loss completely and to prolong animal
survival dramatically.532 Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc.sActRIIB Restores Mass and Strength of Atrophying
Muscle without Affecting Tumor Growth or Fat Loss
in C26-Bearing Mice
Body composition analysis further demonstrated that sActRIIB
completely blocked the loss of lean body mass, but surprisingly
did not inhibit the decrease in fat mass in the C26 mice (Fig-
ure 2A). The weights of extensor digitalis longus (EDL), soleus,
calf and tibialis anterior (TA) muscles in the untreated C26 mice
decreased by more than 25% below levels in normal controls.
However, the weights of all these muscles in sActRIIB-treated
C26 mice were similar to or even greater than those in controls.
Thus, the treatment fully protected the fast-twitch (EDL), slow-
twitch (soleus) and mixed-fiber (calf and TA) muscles against
cancer-associated atrophy (Figure 2A). Furthermore, the grip
strength of the untreated C26 mice declined in parallel with the
muscle weights. However, the sActRIIB treatment completely
restored grip strength to above the normal levels (Figure 2B).
Thus, the sActRIIB treatment caused a buildup of functional
muscle in the tumor-bearing animals to levels resembling or
exceeding control levels.
To monitor possible effects of sActRIIB on growth of the C26
tumor, we measured tumor sizes and weights. As shown in
Figure 2C, sActRIIB treatment had no effect on C26 tumor
growth rate or weight. Thus, the dramatic muscle sparing is
clearly not due to elimination of the primary tumor. Also, because
neither fat mass nor tumor growth was affected by the treatment,
the prolongation of survival in the C26 mice must be attributable
to the large muscle sparing effect of sActRIIB. Therefore,
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Figure 2. ActRIIB Antagonism Reverses Muscle Wasting in C26 Tumor-Bearing Mice without Affecting Tumor Growth, Fat Loss, or Inflam-
matory Cytokine Levels
(A) sActRIIB prevents loss of lean muscle mass but has no effect on fat loss in C26 mice. Body composition was analyzed at day 25 post tumor implantation.
(B) sActRIIB restores the grip strength of C26 mice beyond normal control level. Grip strength was measured prior to necropsy.
(C) sActRIIB treatment does not alter C26 tumor growth. Tumor sizes were measured longitudinally and tumor weights were measured by necropsy.
(D) Northern blot analysis on myostatin expression in gastrocnemius muscles.
(E) ELISA on serum levels of IL-6, TNF-a and IL-1b.
Values are means ± SEM. *p < 0.05, **p < 0.01; ***p < 0.001. n = 10-12.
See also Table S1.sActRIIB was able to extend the survival by reversing cachexia
even without inhibiting tumor growth.
sActRIIB BlocksMyostatin Overproduction in C26Model
but Does Not Reduce Elevated Levels of IL-6, IL-1b,
or TNF-a
Northern blot analysis of the gastrocnemius muscles of C26-
bearing mice revealed that myostatin mRNA level increased
by more than 2-fold over control level, but sActRIIB treatment
prevented this induction of myostatin (Figure 2D). However, no
change in activin A (bA) mRNA level was detected in the gastroc-
nemius (data not shown). This induction of myostatin in muscle
apparently was triggered by humoral mediator(s) either secreted
by the C26 tumor, which was implanted subcutaneously, or
released by the host in response to the tumor burden. Because
sActRIIB treatment fully abolished themyostatin overexpression,
activation of ActRIIB pathway must be critical for its induction.It is widely believed that proinflammatory cytokines are critical
in the development of cancer cachexia (Argiles & Lopez-Soriano,
1999). To test whether sActRIIB treatment might be achieving its
anti-cachexia effect by attenuating proinflammatory cytokines,
we measured by ELISA the serum levels of IL-6, IL-1b and
TNF-a in the C26 mice. As reported previously, these major
cytokines, especially IL-6, were elevated in the circulation in
C26 mice (Strassmann et al., 1992; Tanaka, et al., 1993). Unex-
pectedly, the sActRIIB treatment did not change the levels of
these cytokines (Figure 2E), and thus they cannot account for
the reversal of cachexia seen upon sActRIIB treatment. These
findings imply that increased levels of IL-6 by itself can not
induce the cachectic syndrome. To test this conclusion, we
treated normal adult mice with a pharmacological dose of re-
combinant IL-6 by continuous infusion, but found no significant
change in either body weight or muscle mass (Table S1). Thus,
in the C26 model, ligands of the ActRIIB pathway appear to beCell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc. 533
more important than proinflammatory cytokines in triggering
muscle wasting and cachexia.
ActRIIB Antagonism Reverses Muscle Wasting,
Ameliorates Anorexia, and Prolongs Survival
in Inhibin-Deficient Mice
To examine whether ActRIIB pathway blockade is also effective
in reversing muscle wasting induced by other cancers, we
administered sActRIIB to inhibin-a knockout (KO) mice, which
spontaneously form gonadal tumors and manifest marked
cachexia (Matzuk et al., 1994). It has been reported that genetic
crossing of inhibin-a KOmice with follistatin transgenic or ActRII
(ActRIIA) KO mice slows both tumor formation and development
of weight loss (Cipriano et al., 2000; Coerver et al., 1996). Also,
administration of ActRIIA-Fc (a soluble receptor different from
the sActRIIB studied here) to 3-week-old inhibin-deficient mice
(when neither cachexia nor tumor was evident) had similar bene-
ficial effects on body weight and tumor growth (Li et al., 2007).
Thus, blocking deregulated activins before disease onset in
inhibin-deficient mice slowed the development of tumor
cachexia. However, it is unclear whether inhibiting activins after
tumors and weight loss have fully developed in these mice could
have any beneficial effect on tumor growth, cachexia, or both.
This question is of therapeutic importance, since cachexia is
generally found in patients with advanced cancers. Also, none
of these studies examined muscle wasting, the most debilitating
aspect of cachexia. Here, we administered sActRIIB to the
inhibin-a KO mice after tumor cachexia had advanced to a late
stage and analyzed the effects on muscle wasting, anorexia
and survival.
By 8 weeks of age, the weights of the male and female inhibin-
a KO mice were 10%–17% lower than those of age-matched
wild-type (WT) controls. We initially administered sActRIIB to
the KOmice at 8 weeks of age. The WT mice grew steadily while
the untreated KO mice of both sexes suffered dramatic weight
loss, and nearly all died within a 10-week period (Figure 3A). It
should be noted that the plot of the weights of the surviving
KO mice against time (Figure 3A) underestimates the actual
weight loss of the inidividual untreated KO mice, because those
animals showing greatest weight loss died sooner and thus
steadily dropped out from the plots of mean body weights. In
fact, individual body weight analysis indicates that at death,
the untreated KO mice had lost an average of 24% (p < 0.001)
of their initial body weights (i.e., at 8 weeks of age), and their
mean muscle mass diminished to less than 50% of that of WT
control (p < 0.001) (Figure S3A). However, within one week of
treatment with sActRIIB, the body weights of both male and
female KO mice increased rapidly and reached levels in the
WT littermates. With continued sActRIIB treatment, their body
weights even exceeded the WT controls (Figure 3A). Remark-
ably, along with the body weight improvement, a dramatic
prolongation in survival was observed in the sActRIIB-treated
KO mice (p < 0.0001). In fact, when 100% of the untreated
male and female KO mice had died, nearly all the treated males
and 85% of the treated females were still alive (Figure 3A).
To test the ability of sActRIIB to reverse muscle loss and
cachexia-anorexia syndrome, we then administered a single
dose to 8-week-old male and 12-week-old female KO mice. By534 Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc.these ages, gonadal tumors and cachexia had developed to an
advanced stage in these KOmice with the animals loosing about
22%–28% of their muscle mass compared to their WT controls
(Figure S3B). We analyzed the mice 14 days after the single
dose. In the absence of sActRIIB treatment, body weights,
food intake, lean body mass, fat mass, and mass of the gastroc-
nemius in the male and female KO mice were 20%–45% lower
than those in the WT controls (Figure 3B and Figure S3C).
However, sActRIIB treatment rapidly reversed all these parame-
ters back to or even beyond the levels in the WT controls.
Notably, a single injection of sActRIIB was able to cause the
doubling of the mass of gastrocnemius muscle in the KO mice
within two weeks (Figure 3B).
To determine how these ActRIIB pathway perturbations affect
muscle function, we analyzed the myosin heavy chain contents
as well as muscle grip strength in the inhibin-a KO mice. As
shown by western blot analysis, the content of myosin heavy
chain in the gastrocnemius was lower in the untreated KO
mice than in WT controls, but after sActRIIB treatment, it was
increased to an even higher level than in the WT (Figure 3C).
Concomitantly, sActRIIB treatment fully restored the weakened
grip strength to above normal control levels (Figure 3D). Thus,
sActRIIB promoted a buildup of functional muscle and was
highly effective in ameliorating all aspects of the cachexia
syndrome, including anorexia and fat loss, in the inhibin-deficient
animals.
Because of these profound effects on the survival of inhibin-
a KOmice, we examined the impact of sActRIIB on the progres-
sion of the gonadal tumors, after they had been already extab-
lished in these male and female KO mice. Surprisingly, a single
doseof sActRIIBcausedadramatic suppressionof theadvanced
ovarian and testicular tumors in these mice (Figure S3D).
sActRIIB Sequesters Activin A and Myostatin In Vivo
To understand how ActRIIB ligand levels may change in
response to sActRIIB treatment, we measured the amounts of
circulating activin A and myostatin in the inhibin-a KO mice.
Serum activin A levels weremuch higher in bothmale and female
KO mice than in WT controls; but, a single dose of sActRIIB
completely abolished the increase in activin A within two weeks.
By contract, serum myostatin levels in KO mice did not differ
significantly from WT levels, but were markedly suppressed by
sActRIIB treatment (Figure 3E). Thus, sActRIIB neutralized both
activin A and myostatin in vivo, and these actions can account
for the therapeutic effects on cachexia, tumorigenesis and
survival in the inhibin-deficient animals.
ActRIIB Antagonism Reverses Cancer-Induced Atrophy
of the Heart
During cancer cachexia in both the C26 tumor-bearing mice and
inhibin-deficient mice with advanced gonadal cancers, there
was a marked diminution in heart mass that was evident on
necropsy. The average heart weights in these cachectic animals
decreased by 20%–29% compared to the normal controls, and
a dramatic reduction in ventricular wall thickness was evident
upon histological examination of the cardiac cross-sections.
Remarkably, sActRIIB treatment completely blocked the cardiac
atrophy in both C26 mice and inhibin-deficient mice (Figure 4).
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Figure 3. sActRIIB Treatment Completely Reverses Muscle Loss and Anorexia and Dramatically Prolongs Lifespan in Inhibin-a KO Mice
(A) Changes in body weights and survival rates in male and female inhibin-a KO mice in response to sActRIIB. 8-week-old KO mice received either PBS or
sActRIIB (10 mg/kg, SC, weekly). Age-matched WT mice received PBS.
(B) Effect of a single dose of sActRIIB on body weight, food intake, body composition and muscle mass in male inhibin-a KOmice. 8-week-old KOmice received
a single injection of sActRIIB (30 mg/kg, SC) or PBS. Age-matched WT mice were used as control. Necropsy was performed at 14 days after injection.
(C) Western blot analysis on myosin heavy chain (MHC) contents of gastrocnemius muscles.
(D) A single dose of sActRIIB fully restores the grip strength. Grip strength was measured at day 14.
(E) Changes in serum activin A and myostatin levels in male and female KO mice in response to sActRIIB.
Values are means ± SEM. Survival studies: ###p < 0.0001; n = 20-25 per KO group; n = 17-19 per WT group. Other studies: *p < 0.05, **p < 0.01, ***p < 0.001;
n = 10-12.
See also Figure S3.Thus cardiac atrophy is an important but unappreciated feature
of cancer cachexia and seems to result from enhanced ActRIIB
signaling. Interestingly, in contrast to our findings in skeletal
muscle described below, we found no change in the atrophic
hearts in expression of atrophy-specific ubiquitin ligases or in
BrdU labeling following sActRIIB treatment (data not shown).
Therefore, the biochemical mechanisms of this dramatic cardiac
atrophy and re-growth clearly require further investigations.
Elevated Activin Is Critical in the Pathogenesis
of Muscle Wasting and Anorexia Associated
with Multiple Cancers
To investigate whether elevated activin A can cause cachexia,
we implanted adult nude mice with CHO cells that had been
transfected with activin A (CHO-Activin). The resulting overpro-
duction of activin A in these xenograft-bearing mice led toprogressive weight loss, depressed food intake, muscle wasting,
and death (Figure 5A). To verify that this lethal wasting syndrome
resulted from the elevated activin A, we administered an anti-
activin A antibody to the CHO-Activin implantedmice. This treat-
ment prevented the weight loss, anorexia, muscle wasting and
the rapid death of these xenograft-bearing animals (Figure 5A).
The CHO-Activin-bearing mice also lost up to 30% of their fat
mass (p < 0.01), and this loss was completely prevented by
anti-activin A antibody treatment. Thus, elevated activin A can
play a causal role in the development of muscle wasting and
cachexia-anorexia syndrome.
It is noteworthy that activin overexpression also caused the
decrease in food intake in theCHO-Activin implantedmice, since
the activin A-neutralizing antibody completely blocked this
effect. This finding is consistent with our observation that the
depressed food intake in the inhibin-a KO mice was completelyCell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc. 535
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Figure 4. C26 Tumor-Bearing Mice and
Inhibin-a KO Mice Show Marked Cardiac
Atrophy that Is Completely Reversed by
ActRIIB Antagonism
(A) sActRIIB reverses heart atrophy in C26 mice.
Cachectic C26 mice were treated with sActRIIB
(10 mg/kg, SC, weekly) or PBS. As control, age-
matched normal mice received PBS. Heart
weights were determined via necropsy after
2 weeks of treatment. Values are means ± SEM.
**p < 0.01; n = 6.
(B and C) sActRIIB treatment ameliorates heart
atrophy in inhibin-a KO mice. 8-week-old KO
males (B) and 12-week-old KO females (C) (both
carrying advanced gonadal tumors) were treated
with a single dose of sActRIIB (30 mg/kg, SC) or
PBS. Age-matched WT males and females were
used as normal controls. Heart weights were
determined by necropsy 2 weeks after treatment.
Values are means ± SEM. **p < 0.01,
***p < 0.001; n = 9-10.
(D) sActRIIB treatment reverses the reduction in
ventricular wall thickness in inhibin-a KO mice.
Representative images of PAS-stained heart
cross-sections from WT (left), untreated KO
(middle) and sActRIIB-treated KO (right) mice are
shown.reversed by sActRIIB treatment (Figure 3B). Thus, elevated
activin A mediates anorexia, although the mechanism by which
activin A regulates food intake is unclear and warrants further
investigation.
To determine the importance of this anorexia in mediating
activin-induced wasting, we pair fed the CHO-Vector implanted
mice with a reduced amount chow equal to that consumed by
the CHO-Activin implanted mice. The pair feeding resulted in a
loss of about 5% body weight and lean mass in the CHO-Vector
implanted mice. By contrast, the CHO-Activin implanted mice
lost over 20% of their mean body weight and lean mass during
the same period. The pair feeding also had no effect on the
survival of the CHO-Vector bearing mice. In contrast, 100% of
the CHO-Activin bearing mice died by the end of the experiment
(Figure S4A). Thus, although elevated activin A markedly
reduces food intake, the decrease in nutrient intake can account
for only a minor portion of the body wasting induced by the acti-
vin-secreting tumor, and the major fraction of weight loss must
be due to activin A-induced tissue catabolism.
To further investigate the role of activin A in the pathogenesis
of cancer cachexia, we implanted nude mice with the human
ovarian cancer TOV-21G (Provencher et al., 2000) or human
melanomaG361 (Mori et al., 1991). These tumor lineswere found
to secrete in vitro higher amounts of activin A as compared to
a variety of other cancer lines examined (Figure 5B). Implantation
of these tumors as xenografts in nudemice resulted in significant
weight loss, muscle wasting, reduced food intake and fat loss, all
of which were fully prevented by sActRIIB treatment (Figures 5C
and 5D). In addition, sActRIIB also suppressed the growth of
TOV-21G and G361 xenografts in nudemice (Figure S4B). These
observations on the activin A-secreting xenograft are similar to
our findings on the inhibin-a KO mice and provide further
evidence that ActRIIB ligands, especially activin A, are critical536 Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc.in the muscle wasting associated with various cancers as well
as in the progression of certain tumors.
ActRIIB Pathway Inhibition Attenuates the Accelerated
Muscle Protein Catabolism during Cancer Cachexia
There is mounting evidence that the ubiquitin-proteasome
system mediates the breakdown of the bulk of muscle proteins,
and its activation accounts for much of the accelerated muscle
proteolysis in various catabolic disease states (Cohen et al.,
2009; Mitch & Goldberg, 1996). In the atrophying muscles,
multiple components of this pathway are induced, including
the muscle-specific E3 ligases, Atrogin-1 and MuRF1, and their
induction is essential in rapid atrophy (Bodine et al., 2001;
Gomes et al., 2001). To determine whether the ActRIIB pathway
might regulate these critical components during cancer
cachexia, we examined by Northern the levels of ubiquitin (Ub),
Atrogin-1 and MuRF1 in gastrocnemius muscles of C26 mice
and inhibin-a KO mice (Figure 6A). mRNA levels for these
atrophy-related genes in the gastrocnemius were markedly
increased above control levels in both cachexia models, but
sActRIIB treatment completely abolished their induction (Fig-
ure 6A). Thus, antagonism of the ActRIIB pathway prevents the
activation of key components of the ubiquitin-proteasome
pathway during cancer cachexia.
In various types of muscle atrophy, there is a general acceler-
ation of protein ubiquitination, which is demonstrable in muscle
extracts (Kwak et al., 2004; Solomon et al., 1998). To investigate
the effects of sActRIIB treatment on muscle protein ubiquitina-
tion, we examined rates of ubiquitin conjugation to endogenous
proteins in the gastrocnemius from inhibin-a KOmice. As shown
in Figure 6B, there was a sharp rise in ubiquitin conjugation
in muscle extracts of the KO mice, which was prevented by
sActRIIB treatment. Thus, sActRIIB blocked the enhanced
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Figure 5. sActRIIB Treatment Prevents the Development of Cachexia-Anorexia Syndrome in Nude Mice Bearing Activin A-Secreting Xeno-
grafts
(A) Activin A-overexpressing CHO xenografts results in a lethal muscle wasting-anorexia syndrome in nude mice. Nude mice were each implanted with 3X106
CHO-Activin or CHO-Vector cells. CHO-Activin xenograft-bearing mice were treated with activin A antibody (Activin Mab) (20 mg/kg, SC, 2X/week) or PBS.
Changes in body weight, lean body mass, food intake and survival rate are shown.
(B) Activin A secretion levels of various human cancer cell lines in vitro. All the cancer cell lines were cultured for 68 hr and the medium was analyzed by ELISA.
TOV-21G and melanoma G361 (red) were selected for xenograft studies in nude mice.
(C) sActRIIB prevents weight loss, anorexia, and loss of muscle and adipose tissues in nude mice bearing TOV-21G xenografts.
(D) sActRIIB prevents weight loss, muscle wasting and fat loss in nude mice bearing G361 xenografts.
Values are means ± SEM. **p < 0.01, ***p < 0.001; ***p < 0.0001 on survival rate. n = 12.
See also Figure S4.ubiquitination in muscle that is characteristic of the cachectic
state. To explore the mechanism by which ActRIIB pathway
regulates the atrophy-specific ubiquitin ligases, we assayed by
western blot the activities of Smad and FOXO signaling systems
in muscles of inhibin-a KO and control mice. As expected, phos-
pho-Smad2 wasmarkedly increased in the gastrocnemius of KO
mice above levels in WT, and sActRIIB treatment completely
blocked this Smad2 activation (Figure 6C).
Smad and FOXO signal transduction systems can influence
each other’s activity (Seoane et al., 2004), and in skeletal muscle,
the myostatin-Smad pathway stimulates FOXO function (Sartori
et al., 2009; Trendelenburg et al., 2009). FOXO3 activation has
been shown to induce Atrogin-1 and MuRF1 transcription, stim-
ulate proteolysis and cause atrophy (Mammucari et al., 2007;Sandri et al., 2004; Zhao et al., 2007). Since Smad2 signaling
was activated in muscles of the inhibin-a KO mice and sup-
pressed by sActRIIB treatment, we investigated FOXO3 activity
in these tissues. Western blot analysis revealed an increase
in total FOXO3a content, along with a decrease in the inactive
species phospho-FOXO3a in the gastrocnemius of the KO
mice, compared to levels in control mice (Figure 6D). These find-
ings indicate FOXO3a activation, since only dephosphorylated
FOXO3a enters the nucleus and stimulates transcription. sAc-
tRIIB treatment decreased the total FOXO3a content and
increased phospho-FOXO3a in the gastrocnemius of the KO
mice. This reduction in FOXO activity suggests activation of
the PI3K-AKT pathway, which causes FOXO phosphorylation
(Figure 6D). Accordingly, western blot analysis demonstratedCell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc. 537
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Figure 6. sActRIIB Attenuates the Accelerated Muscle Protein Catabolism during Cancer Cachexia
(A) Northern blot analysis on Ub, Atrogin-1 and MuRF1 in gastrocnemius muscles of C26 mice and inhibin-a KO mice.
(B) sActRIIB inhibits the accelerated Ub-conjugation in atrophying muscle in inhibin-a KO mice.
(C–E) Western blot on Smad2 (C), FOXO3a (D) and AKT (E) in gastrocnemius muscles of inhibin-a KO mice.
n = 8-10.an increase in AKT activity in the gastrocnemius of the sActRIIB-
treated KO mice (Figure 6E). Together, these observations
provide strong direct evidence that enhanced Smad2 activity
activates FOXO3a signaling in muscle and helps to explain
the profound inhibition by sActRIIB of Atrogin-1 and MuRF1
induction.
ActRIIB Pathway Inhibition Stimulates Muscle
Stem Cell Growth in Atrophied Muscle
Morphometric analysis of the gastrocnemius showed that the
average cross-sectional area of myofibers in the inhibin-a KO
mice was 42% smaller than that in WT controls (Figure 7A).
Two weeks after a single injection of sActRIIB, the average
myofiber area in the KOmice was massively increased (by about
110%) and had become 48% larger than in the controls. Thus,
sActRIIB treatment not only prevents atrophy but can also cause
hypertrophy. This dramatic growth upon blocking the ActRIIB
pathway led us to investigate the effects of sActRIIB administra-
tion on muscle stem cell activity. The stem cells present in adult
muscles are the satellite cells, which reside between the base-
ment membrane and sarcolemma of myofibers as morphologi-
cally distinct, mononucleated cells (Mauro, 1961). Satellite cells538 Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc.are normally quiescent but can proliferate rapidly in response
to exercise, injury and various anabolic stimuli to promote
muscle hypertrophy or regeneration (Dhawan & Rando, 2005;
Kuang & Rudnicki, 2008). Genetic ablation of myostatin has
been reported to cause satellite cell activation (McCroskery
et al., 2003). To test whether ActRIIB antagonism may activate
satellite cells in normal and atrophied muscles, we performed
in vivo BrdU labeling and analyzed the cross-sections ofmuscles
for sActRIIB-induced changes in BrdU staining and in satellite
cell markers, Pax7 and M-cadherin (Kuang & Rudnicki, 2008;
Moore and Walsh, 1993; Relaix et al., 2006). sActRIIB treatment
dramatically increased the numbers of BrdU-, Pax7- andM-cad-
herin-positive nuclei per myofiber in both WT and KO mice
(Figures 7B and 7C; Table S2). A small proportion of Pax7-posi-
tive nuclei and the majority of the M-cadherin-positive nuclei
were doubly labeled for BrdU (Figure 7C). Similar results were
obtained in C26 mice (Figure S5). Thus, the ActRIIB-Smad
pathway is critical in maintaining the quiescence of satellite cells
in both normal and cachectic muscles. Importantly, these find-
ings suggest that in severely atrophiedmuscles, some quiescent
satellite cells with strong proliferative potential are present and
can grow rapidly upon ActRIIB blockade.
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Figure 7. sActRIIB Treatment Increases Myofiber Size and Stimulates Satellite Cell Growth in Normal and Atrophying Muscles
(A) A single dose of sActRIIB rapidly reverses myofiber atrophy in inhibin-a KOmice. WT and KOmice (8-week-old) were treated with sActRIIB (30 mg/kg, SC) or
PBS for two weeks. Representative images of the gastrocnemius cross-sections stained with anti-laminin antibody (top) and muscle morphometry data (bottom)
are shown.
(B) Counts of BrdU-, Pax7-, and M-cadherin-immunoreactive cells in muscle cross-sections. WT and inhibin-a KO mice received a single injection of PBS or
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(C) Representative images of gastrocnemius cross-sections double-labeled with antibodies against BrdU and Pax7 or BrdU and M-cadherin. Arrows point to
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See also Table S2 and Figure S5.DISCUSSION
Although cachexia is a highly debilitating syndrome character-
istic of many cancers, it remains a poorly understood process
whose mechanisms have received only limited attention from
cancer researchers. In addition to reducing the patient’s quality
of life (e.g., strength, endurance, and probably his/her suscepti-
bility to other disease processes), progression of body wasting
has poor prognostic implications. In fact, it has often been stated
that cachexia is a causative factor in the patients’ downhill
course, and that a large fraction of cancer deaths is due to this
cachectic state. However, direct evidence linking muscle
wasting to survival of the tumor-bearing organism has been lack-
ing until now. The present findings in the C26 tumor-bearing
mice represent the first clear experimental demonstration that
preserving muscle mass is of major importance in determining
the organism’s survival. In these cachectic mice, ActRIIB antag-
onism dramatically prolonged survival and not only prevented
muscle wasting but even induced net muscle growth, without
altering fat mass or growth of the tumor. Therefore, development
of treatments that block these catabolic actions of the tumor
should be a major therapeutic objective, not just to enhance
the quality of life, but also to prolong survival.
The mechanisms signaling the cachectic state have been
controversial, and the pathophysiological basis of the musclewasting in cancer is difficult to unravel. Although the loss of
muscle mass clearly can be due to tumor-derived factors, their
role is complicated by the associated anorexia, the decreased
nutrient supply, and the resulting endocrine changes (e.g.,
insulin-deficiency, increased glucocorticoids and IGF-1).
However, it is now clear that tumor-induced wasting, excessive
muscle proteolysis and activation of the ubiquitin proteasome
system also occur in pair-fed animals, and a variety of cytokines,
especially IL-6, TNF-a and IL-1b, have been proposed to trigger
this wasting. However, the present studies fail to support impor-
tant roles for these factors; in fact, we failed to observe any cata-
bolic effect upon infusion of IL-6. Instead, our findings argue
strongly for a dominant role of ActRIIB pathway in the activation
of muscle wasting during cancer cachexia: (1) Inhibition of the
ActRIIB pathway fully reversed the muscle loss during cancer
cachexia, even without affecting the elevated inflammatory cyto-
kine levels; (2) ActRIIB pathway activation induced the ubiquitin
ligases critical in muscle wasting and enhanced ubiquitination
of muscle proteins, and these effects were completely abolished
by sActRIIB; (3) In the tumor-bearing mice, ActRIIB-Smad sig-
naling stimulated FOXO3 activity in muscle, which induced
transcription of Atrogin-1 and MuRF1; 4) ActRIIB antagonism
dramatically stimulated satellite cell proliferation, which presum-
ably contributes to rapid reversal of muscle loss in the treated
animals.Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc. 539
Typically in cachectic organisms, there is a marked loss of
both muscle and adipose tissues. It is noteworthy, however,
that the dramatic effects of activating or blocking the ActRIIB-
Smad pathway on body weight in the C26 tumor-bearing mice
involved parallel changes only in themass of muscles. Moreover,
the buildup of muscle correlated with greater myosin expression
and increased grip strength. Surprisingly, blocking the ActRIIB
pathway in the C26 mice prevented muscle loss or even
increased muscle mass above normal levels but did not inhibit
adipose tissue loss. Presumably, this continued loss of adipose
tissue mass was due to the continued production of other cyto-
kines (e.g., TNF-a) in the C26-bearing animals, since in the
inhibin-deficient mice and those bearing activin-secreting CHO
tumors, eliminating activin affected muscle and adipose tissue
similarly. Thus, the growth and wasting of these two tissues
can be regulated in distinct fashions, and only the maintenance
of muscle mass correlates with enhanced survival of the
cancer-bearing animals.
The present studies have also uncovered a previously unap-
preciated loss of heart mass in tumor-bearing animals, which
is also completely reversed by blocking the ActRIIB pathway.
Surprisingly, decreased cardiac size has received virtually no
attention in the many recent studies on cancer cachexia, even
though early investigators often reported cardiac atrophy in
patients with cancer, malnutrition, as well as infections (Heller-
stein and Santiago-Stevenson 1950). In C26 tumor-bearing
mice and inhibin-deficient mice with gonadal cancers, the heart
was found to atrophy by 20%–29%, which approached the loss
of skeletal muscle. Furthermore, blocking the ActRIIB pathway
completely normalized the heart mass in these tumor-bearing
animals. Unlike skeletal muscle, the hearts of the tumor-bearing
animals did not show the marked induction of Atrogin-1 or
MuRF1. The cellular mechanisms of this severe cardiac atrophy
and re-growth and how increased signaling by the ActRIIB
pathway influences cardiac size and performance will be impor-
tant issues for future study. It is noteworthy that myostatin and
activin have been implicated in cardiac failure (Heineke et al.,
2010; Rodgers et al., 2009; Springer et al., 2010; Yndestad
et al., 2004). Presumably, the reversal of cardiac atrophy, in
addition to the restoration of skeletal muscle, contributed to
the prolongation of lifespan in the tumor-bearing animals seen
upon ActRIIB blockade. Further studies will be needed to eval-
uate the functional impact of cancer-induced heart atrophy, as
well as its reversal by sActRIIB, to cardiac performance.
As noted above, cancer cachexia is also associated with
anorexia, which may also contribute to the loss of muscle
mass and the patient’s downhill course. In the present studies,
the ActRIIB treatment markedly stimulated food intake in the
inhibin-deficient mice, the activin-secreting CHO tumors, and
human tumor xenografts-bearing mice back to or above control
levels. These findings indicate that enhanced activin signaling
reduces appetite and food intake, but the mechanisms for this
marked effect remain to be elucidated. Although increased
nutrient intake probably played some role in the dramatic muscle
growth and enhancing survival, our studies on pair-fed animals
indicate that the decreased food intake in response to high circu-
lating levels of activin A accounts at most for a small fraction of
the loss of body weight (Figure S4A), and thus enhanced tissue540 Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc.catabolism seems a more important cause of the wasting
syndrome.
While these insights advance our understanding of the impor-
tance of ActRIIB pathway in the pathogenesis of the cachexia-
anorexia syndrome, additional investigations will obviously be
required to clarify the therapeutic value of ActRIIB antagonism
in treating the debilitating wasting associated with diverse tumor
types and non-malignant diseases (e.g., AIDS, sepsis, burns,
cardiac and renal failure). Numerous reports have documented
increased expression of activin A in cancer patients (Harada
et al., 1996; Otani et al., 2001; Petraglia et al., 1998; Seder
et al., 2009; Thomas, et al., 1997; Wildi et al., 2001), for example,
in patients with solid cancers (Harada et al., 1996) and ones with
endometrial and cervical carcinoma (Petraglia et al., 1998). In the
present studies, about a third of the human tumor xenografts
examined were found to produce large amounts of activin A
(Figure 5B). Elevated serum activin A has also been reported in
patients in various non-malignant diseases, including patients
with renal failure, heart failure and hyperthyroidism (Harada
et al., 1996; Yndestad et al., 2004).
While these findings point to a systemic activation of this
highly catabolic factor in patients with wasting syndromes,
further clinical studies will be needed to define the precise role
of activin A in the cachexia-anorexia syndrome with cancer
and non-malignant diseases and possible contributions of other
factors. Little is known presently about myostatin’s levels in
various human diseases, in part due to the lack of a sensitive
assay of human myostatin. It will also be important to determine
the levels of other ActRIIB pathway ligands and regulatory
factors (e.g., inhibin-a, propeptide and follistatin) in different
cohorts of patients. The dramatic, reversible changes in body
mass shown here emphasize the importance of obtaining such
information not only for understanding disease mechanisms
but also to provide a fuller rationale basis for anti-activin
therapies. However, since the inhibition of ActRIIB signaling by
sActRIIB induces growth of normal muscle (Figure S1B), this
treatment is likely to be anabolic and help combat muscle loss
in many catabolic conditions, even if the wasting is not triggered
by excessive signaling by activin or related ligands of the ActRIIB
pathway.EXPERIMENTAL PROCEDURES
Materials
sActRIIB
The sActRIIB (soluble ActRIIB-Fc) expression construct was engineered by
subcloning a cDNA fragment corresponding to the extracellular domain of
human activin type-2B receptor (aa 7–100) into an IgG2 Fc fusion split vector.
The construct was transfected into CHO cells and the recombinant sActRIIB
was purified from culture medium using a mAb Select SuRe affinity column
(GE) followed by Fractogel chromatography (EMD Chemicals).
Anti-Activin A Antibody
Monoclonal anti-activin A antibody was generated in XenoMouse (Amgen Inc)
using recombinant activin A as an immunogen.
Recombinant IL-6
hu-IL-6 was expressed and purified using mammalian expression system
(Amgen Inc).
Smad 2/3 Reporter Assay
Smad2/3 luciferase reporter construct pLuc-MCS(CAGA)12 was engineered
by subcloning a repeat of twelve GAGA elements into pLuc-MCS (Strategen).
Stably transfected C2C12 myoblasts were used to measure the neutralizing
activity of sActRIIB against myostatin or activin A by luciferase assay
(Promega).
Cell Cultures
The TOV-21G andG361 human cancer cell lines (ATCC) were cultured in RPMI
1640medium supplementedwith 10%FBS. CHOcells were cultured in DMEM
supplemented with 10% FBS (Invitrogen).
Animal Models
Ethics Committee Approval
All mouse experiments were performed with the approval of Institutional
Animal Care and Use Committee and are in accordance with the NIH Guide
for the Care and Use of Laboratory Animals.
C26 Tumor-Bearing Mice
The colon 26 murine adenocarcinoma cells were subcutaneously inoculated
into the flank region of 10-week-old male CDF1 mice (0.5 3 106 cells/mouse).
C26 implantedmice were treated with sActRIIB or PBS at different time points.
Multiple experiments were performed with body weight, body composition,
tumor size, grip strength, and survival rates recorded. Weights of lean carcass,
muscle and tumor were measured via necropsy.
IL-6 infusion
CDF1 mice were infused with recombinant IL-6 or saline (n = 12) by using
osmotic pump (Alzet) at a rate of 1 ml/hr (7.2 mg/day) and analyzed at day 1,
3, and 5 for serum IL-6 exposure levels and changes in body weight and
muscle mass.
Inhibin-a KO Mice
For survival studies, 8-week-old KO mice received sActRIIB (10 mg/kg,
weekly, SC) or PBS with body weights and survival rates recorded. For
single-dose studies, 8-weak-old male and 12-week-old female KO mice
were treated with sActRIIB (30 mg/kg, SC) or PBS for 2 weeks. Changes in
body weight, food intake, body composition and grip strength, and terminal
muscle mass were measured.
Activin A Xenograft-Bearing Mice
CHO cells were stably transfected with activin A expression construct
(CHO-Activin) or vector (CHO-Vector). 3x106 cells were implanted intramuscu-
larly (right quadriceps) in each CD1 nude mouse (CRL). CHO-Activin xenograft
mice were treated with PBS or anti-activin A antibody immediately after
implantation.
TOV-21G and G361 Xenografts-Bearing Nude Mice
5x106 cells of each tumor lines were inoculated subcutaneously into each
athymic or BALB/c nu/nu mouse (Harlan, and CRL). Treatment began at day
12 or 18 after implantation, when the average sizes of TOV-21G and G361
reached 150 mm3 and 130 mm3, respectively.
Body Composition, Muscle Grip Strength, and Tumor Size
Lean body mass and fat mass were measured using nuclear magnetic reso-
nance (NMR; Echo Medical Systems). Forelimb grip strength was measured
with Digital Grip strength meter (Columbus Instruments). Five measurements
with 3 min interval between tests were completed for each mouse. Tumor
size was measured by electronic caliper. Tumor volume (mm3) was based
on tumor length (mm) x width (mm) x height (mm). Terminal tumor weights
were determined by necropsy.
Western Blot
Equal amounts of total protein extracts (30 mg 100 mg) derived from the
gastrocnemius muscles of individual mouse groups were separated by
NuPAGE (Invitrogen), transferred to PVDF membrane and probed with anti-
bodies against Smad 2, phospho-Smad 2, FOXO3a, phospho-FOXO3a, and
AKT (1:1000; Cell Signaling) or myosin heavy chain and phospho-AKT
(1:200; Abcam). The membranes were stripped and re-probed with antibody
against a-tubulin (1:2000; Cell Signaling).
Northern Blot
A pool of 10 mg RNA derived from the gastrocnemius muscles of each mouse
group was fractionated by the Northern gel and probed (see Extended Exper-
imental Procedures and Table S3).Ub-Conjugation Assay
Extracts of gastrocnemius muscles were prepared for each mouse group.
Soluble fractions of the extract proteins were subjected to Ub-conjugation
assays by incubating 30 mg of extracts with 125I-Ub (0.15 mg/ml; 1 3
107 cpm) at 37C for 1 hr in buffer containing 20 mM Tris, (pH 7.5)/1 mM
DTT/5 mM MgCl2/2 mM adenosine 5
0-[g-thio]triphosphate (ATPgS), 0.1 mM
MG-132/0.02 mM ubiquitin aldehyde. The reaction mixtures were fractionated
by SDS-PAGE and autoradiographed (See Extended Experimental
Procedures).
ELISA
Serum myostatin and activin A were assayed by sandwich ELISA employing
a non-competing pair of antibodies for each ligand as described in Extended
Experimental Procedures. Serum TNF-a, IL-1b and IL-6 levels were measured
by using Milliplex MAP mouse cytokine assay kit (Millipore).
Histology
Frozen muscle sections of 8 mm in thickness and formalin-fixed cardiac
sections of 4 mm in thickness were prepared and used (see Extended Experi-
mental Procedures).
Immunofluorescence Staining of Satellite Cells
Muscle sections in vivo-labeled with BrdU were subjected to immunofluores-
cence labeling with antibodies against BrdU, Pax7 and M-cadherin and
analyzed as detailed in Extended Experimental Procedures.
Statistics
Groups of tissue weights were compared using Student’s t test. Longitudinal
body weight or musclemass differenceswere analyzed by repeated-measure-
ment ANOVA. Survival rate difference was determined by Chi-Square test.
P values < 0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental information includes Extended Experimental Procedures, five
figures, and three tables can be found with this article online at doi:10.1016/
j.cell.2010.07.011.
ACKNOWLEDGMENTS
We thank Dr. Martin Matzuk for breeding pairs of inhibin-a KO mice. We also
thank Amgen Protein Science for reagent support, George Doellgast for PK
assay, Keith Kelley for confocal microscopy and Keith Langley for helpful
comment.
X.Z., J.L.W., J.L., Y.S., K.S.K., R.R., Q.J., Q.C., T.B., W.S.S., D.L.L. and
H.Q.H. are all current or former employees of Amgen Inc. A.L.G. is professor
of Harvard Medical School and has a consulting agreement with Amgen. His
research is supported by grants from the National Institutes of Health (NIA)
and the Muscular Dystrophy Association.
Received: February 25, 2010
Revised: June 1, 2010
Accepted: July 2, 2010
Published: August 19, 2010
REFERENCES
Acharyya, S., Butchbach, M., Sahenk, Z., Wang, H., Saji, M., Carathers, M.,
Ringel, M., Skipworth, R., Fearon, K., and Hollingsworth, M. (2005). Dystrophin
glycoprotein complex dysfunction: A regulatory link between muscular
dystrophy and cancer cachexia. Cancer Cell 8, 421–432.
Argiles, J.M., and Lopez-Soriano, F.J. (1999). The role of cytokines in cancer
cachexia. Med. Res. Rev. 19, 223–248.
Bodine, S.C., Latres, E., Baumhueter, S., Lai, V.K., Nunez, L., Clarke, B.A.,
Poueymirou, W.T., Panaro, F.J., Na, E., Dharmarajan, K., et al. (2001).Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc. 541
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science
294, 1704–1708.
Cipriano, S.C., Chen, L., Kumar, T.R., and Matzuk, M.M. (2000). Follistatin is
a modulator of gonadal tumor progression and the activin-induced wasting
syndrome in inhibin-deficient mice. Endocrinology 141, 2319–2327.
Coerver, K.A., Woodruff, T.K., Finegold, M.J., Mather, J., Bradley, A., and
Matzuk, M.M. (1996). Activin signaling through activin receptor type II causes
the cachexia-like symptoms in inhibin-deficient mice. Mol. Endocrinol. 10,
534–543.
Cohen, S., Brault, J.J., Gygi, S.P., Glass, D., Valenzuela, D.M., Gartner, C.,
Latres, E., and Goldberg, A.L. (2009). During muscle atrophy, thick, but not
thin filament components are degraded by MuRF1-dependent ubiquitylation.
J. Cell Biol. 185, 1083–1095.
Costelli, P., Muscaritoli, M., Bonetto, A., Penna, F., Reffo, P., Bossola, M.,
Bonelli, G., Doglietto, G.B., Baccino, F.M., and Fanelli, F.R. (2008). Muscle
myostatin signalling is enhanced in experimental cancer cachexia. Eur. J.
Clin. Invest. 38, 531–538.
Dhawan, J., and Rando, T.A. (2005). Stem cells in postnatal myogenesis:
molecular mechanisms of satellite cell quiescence, activation and replenish-
ment. Trends Cell Biol. 15, 666–673.
Fearon, K.C. (2008). Cancer cachexia: developing multimodal therapy for
a multidimensional problem. Eur. J. Cancer 44, 1124–1132.
Glass, D.J. (2005). Skeletal muscle hypertrophy and atrophy signaling
pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984.
Gomes, M.D., Lecker, S.H., Jagoe, R.T., Navon, A., and Goldberg, A.L. (2001).
Atrogin-1, a muscle-specific F-box protein highly expressed during muscle
atrophy. Proc. Natl. Acad. Sci. USA 98, 14440–14445.
Harada, K., Shintani, Y., Sakamoto, Y., Wakatsuki, M., Shitsukawa, K., and
Saito, S. (1996). Serum immunoreactive activin A levels in normal subjects
and patients with various diseases. J. Clin. Endocrinol. Metab. 81, 2125–2130.
Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., and
Molkentin, J.D. (2010). Genetic Deletion of Myostatin From the Heart Prevents
Skeletal Muscle Atrophy in Heart Failure. Circulation 121, 419–425.
Hellerstein, H.K., and Santiago-Stevenson, D. (1950). Atrophy of the Heart: A
Correlative Study of Eighty-Five Proved Cases. Circulation 1, 93–126.
Kuang, S., and Rudnicki, M.A. (2008). The emerging biology of satellite cells
and their therapeutic potential. Trends Mol. Med. 14, 82–91.
Kwak, K.S., Zhou, X., Solomon, V., Baracos, V.E., Davis, J., Bannon, A.W.,
Boyle, W.J., Lacey, D.L., and Han, H.Q. (2004). Regulation of protein
catabolism by muscle-specific and cytokine-inducible ubiquitin ligase
E3alpha-II during cancer cachexia. Cancer Res. 64, 8193–8198.
Lee, S.J., and McPherron, A.C. (2001). Regulation of myostatin activity and
muscle growth. Proc. Natl. Acad. Sci. USA 98, 9306–9311.
Lee, S.J., Reed, L.A., Davies, M.V., Girgenrath, S., Goad, M.E., Tomkinson,
K.N., Wright, J.F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005).
Regulation of muscle growth by multiple ligands signaling through activin
type II receptors. Proc. Natl. Acad. Sci. USA 102, 18117–18122.
Li, Q., Kumar, R., Underwood, K., O’Connor, A.E., Loveland, K.L., Seehra, J.S.,
and Matzuk, M.M. (2007). Prevention of cachexia-like syndrome development
and reduction of tumor progression in inhibin-deficient mice following admin-
istration of a chimeric activin receptor type II-murine Fc protein. Mol. Hum.
Reprod. 13, 675–683.
Mammucari, C., Milan, G., Romanello, V., Masiero, E., Rudolf, R., Del Piccolo,
P., Burden, S.J., Di Lisi, R., Sandri, C., Zhao, J., et al. (2007). FoxO3 controls
autophagy in skeletal muscle in vivo. Cell Metab. 6, 458–471.
Matzuk, M.M., Finegold, M.J., Mather, J.P., Krummen, L., Lu, H., and Bradley,
A. (1994). Development of cancer cachexia-like syndrome and adrenal tumors
in inhibin-deficient mice. Proc. Natl. Acad. Sci. USA 91, 8817–8821.
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J. Biophys. Biochem.
Cytol. 9, 493–495.542 Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc.McCroskery, S., Thomas, M., Maxwell, L., Sharma, M., and Kambadur, R.
(2003). Myostatin negatively regulates satellite cell activation and self-renewal.
J. Cell Biol. 162, 1135–1147.
Mitch, W.E., and Goldberg, A.L. (1996). Mechanisms of muscle wasting. The
role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897–1905.
Moore, R., and Walsh, F.S. (1993). The cell adhesion molecule M-cadherin is
specifically expressed in developing and regenerating, but not denervated
skeletal muscle. Development 117, 1409–1420.
Mori, M., Yamaguchi, K., Honda, S., Nagasaki, K., Ueda, M., Abe, O., and Abe,
K. (1991). Cancer cachexia syndrome developed in nude mice bearing mela-
noma cells producing leukemia-inhibitory factor. Cancer Res. 51, 6656–6659.
Otani, T., Minami, S., Yamoto, M., and Umesaki, N. (2001). Production of
activin A in hyperplasia and adenocarcinoma of the human endometrium.
Gynecol. Oncol. 83, 31–38.
Petraglia, F., Florio, P., Luisi, S., Gallo, R., Gadducci, A., Vigano`, P., Di Blasio,
A.M., Genazzani, A.R., and Vale,W. (1998). Expression and secretion of inhibin
and activin in normal and neoplastic uterine tissues. High levels of serum
activin A in women with endometrial and cervical carcinoma. J. Clin.
Endocrinol. Metab. 83, 1194–1200.
Provencher, D.M., Lounis, H., Champoux, L., Tetrault, M., Manderson, E.N.,
Wang, J.C., Eydoux, P., Savoie, R., Tonin, P.N., and Mes-Masson, A.M.
(2000). Characterization of four novel epithelial ovarian cancer cell lines.
In Vitro Cell. Dev. Biol. 36, 357–361.
Relaix, F., Montarras, D., Zaffran, S., Gayraud-Morel, B., Rocancourt, D.,
Tajbakhsh, S., Mansouri, A., Cumano, A., and Buckingham, M. (2006). Pax3
and Pax7 have distinct and overlapping functions in adult muscle progenitor
cells. J. Cell Biol. 172, 91–102.
Rodgers, B.D., Interlichia, J.P., Garikipati, D.K., Mamidi, R., Chandra, M.,
Nelson, O.L., Murry, C.E., and Santana, L.F. (2009). Myostatin represses
physiological hypertrophy of the heart and excitation-contraction coupling.
J. Physiol. 15, 4873–4886.
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K.,
Schiaffino, S., Lecker, S.H., and Goldberg, A.L. (2004). Foxo transcription
factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal
muscle atrophy. Cell 117, 399–412.
Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R.,
and Sandri, M. (2009). Smad2 and 3 transcription factors control muscle
mass in adulthood. Am. J. Physiol. Cell Physiol. 296, C1248–C1257.
Schuelke, M., Wagner, K.R., Stolz, L.E., Hubner, C., Riebel, T., Komen, W.,
Braun, T., Tobin, J.F., and Lee, S.J. (2004). Myostatin mutation associated
with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682–2688.
Seder, C.W., Hartojo, W., Lin, L., Silvers, A.L., Wang, Z., Thomas, D.G.,
Giordano, T.J., Chen, G., Chang, A.C., Orringer, M.B., et al. (2009). Upregu-
lated INHBA expression may promote cell proliferation and is associated
with poor survival in lung adenocarcinoma. Neoplasia 11, 388–396.
Seoane, J., Le, H.V., Shen, L., Anderson, S.A., and Massague, J. (2004).
Integration of Smad and forkhead pathways in the control of neuroepithelial
and glioblastoma cell proliferation. Cell 117, 211–223.
Solomon, V., Baracos, V., Sarraf, P., and Goldberg, A.L. (1998). Rates of
ubiquitin conjugation increase when muscles atrophy, largely through activa-
tion of the N-end rule pathway. Proc. Natl. Acad. Sci. USA 95, 12602–12607.
Souza, T.A., Chen, X., Guo, Y., Sava, P., Zhang, J., Hill, J.J., Yaworsky, P.J.,
and Qiu, Y. (2008). Proteomic identification and functional validation of activins
and bone morphogenetic protein 11 as candidate novel muscle mass regula-
tors. Mol. Endocrinol. 22, 2689–2702.
Springer, J., Adams, V., and Anker, S.D. (2010). Myostatin: Regulator of
Muscle Wasting in Heart Failure and Treatment Target for Cardiac Cachexia.
Circulation 121, 354–356.
Strassmann, G., Fong, M., Kenney, J.S., and Jacob, C.O. (1992). Evidence for
the involvement of interleukin 6 in experimental cancer cachexia. J. Clin.
Invest. 89, 1681–1684.
Tanaka, Y., Eda, H., Tanaka, T., Udagawa, T., Ishikawa, T., Horii, I., Ishitsuka, H.,
Kataoka, T., and Taguchi, T. (1990). Experimental cancer cachexia induced by
transplantable colon 26 adenocarcinoma in mice. Cancer Res. 50, 2290–2295.
Tanaka, M., Miyazaki, H., Takeda, Y., and Takeo, S. (1993). Detection of serum
cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-
bearing mice. Cancer Lett. 72, 65–70.
Thomas, T.Z., Wang, H., Niclasen, P., Obryan, M.K., Evans, L.W., Groome,
N.P., Pedersen, J., and Risbridger, G.P. (1997). Expression and localization
of activin subunits and follistatins in tissues frommen with high grade prostate
cancer. J. Clin. Endocrinol. Metab. 82, 3851–3858.
Tisdale,M.J. (2009).Mechanisms of cancer cachexia. Physiol. Rev.89, 381–410.
Trendelenburg, A.U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., and
Glass, D.J. (2009). Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting
myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 296,
C1258–C1270.Wildi, S., Kleeff, J., Maruyama, H., Maurer, C.A., Buchler, M.W., and Korc, M.
(2001). Overexpression of activin A in stage IV colorectal cancer. Gut 49,
409–417.
Yndestad, A., Ueland, T., Øie, E., Florholmen, G., Halvorsen, B., Attramadal,
H., Simonsen, S., Frøland, S.S., Gullestad, L., Christensen, G., et al. (2004).
Elevated Levels of Activin A in Heart Failure: Potential Role in Myocardial
Remodeling. Circulation 109, 1379–1385.
Zhao, J., Brault, J.J., Schild, A., Cao, P., Sandri, M., Schiaffino, S., Lecker,
S.H., and Goldberg, A.L. (2007). FoxO3 coordinately activates protein
degradation by the autophagic/lysosomal and proteasomal pathways in atro-
phying muscle cells. Cell Metab. 6, 472–483.
Zimmers, T.A., Davies, M.V., Koniaris, L.G., Haynes, P., Esquela, A.F.,
Tomkinson, K.N., McPherron, A.C., Wolfman, N.M., and Lee, S.J. (2002).
Induction of cachexia inmice by systemically administeredmyostatin. Science
296, 1486–1488.Cell 142, 531–543, August 20, 2010 ª2010 Elsevier Inc. 543
